Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q4 FY22 results · Jan–Mar 2022
Supriya Lifescience reported revenue from operations of ₹181.27 crore and net profit of ₹46.21 crore for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 181.27 | — | — | 117.00 | +54.9% |
| Other income | 3.85 | — | — | 5.44 | −29.2% |
| Total income | 185.12 | — | — | 122.44 | +51.2% |
| Profit before tax | 75.48 | — | — | 40.07 | +88.4% |
| Net profit for the period | 46.21 | — | — | 39.64 | +16.6% |
| EPS, basic (₹) | 5.74 | — | — | 4.93 | +16.4% |
| Net margin (%) | 25.5 | — | 33.9 |
Standalone
- Filed with BSE
- 24 May 2022, 16:14 IST
- Board meeting
- 20 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE